Cerebrospinal fluid methylome-based liquid biopsies for accuratemalignant brain neoplasm classification.

Zuccato Jeffrey A et al.

BACKGROUND: Resolving the differential diagnosis between brain metastases (BM), glioblastomas (GBM), and central nervous system lymphomas (CNSL) is an important dilemma for the clinical management of the main three intra-axial brain tumor types. Currently, treatment decisions require invasive diagnostic surgical biopsies that carry risks and morbidity. This study aimed to utilize methylomes from cerebrospinal fluid (CSF), a biofluid proximal to brain tumors, for reliable non-invasive classification that addresses limitations associated with low target abundance in existing approaches. METHODS: Binomial GLMnet classifiers of tumor type were built, in fifty iterations of 80\% discovery sets, using CSF methylomes obtained from 57 BM, GBM, CNSL, and non-neoplastic control patients. Publicly-available tissue methylation profiles (N=197) on these entities and normal brain parenchyma were used for validation and model optimization. RESULTS: Models reliably distinguished between BM (area under receiver operating characteristic curve [AUROC]=0.93, 95\% confidence interval [CI]: 0.71-1.0), GBM (AUROC=0.83, 95\% CI: 0.63-1.0), and CNSL (AUROC=0.91, 95\% CI: 0.66-1.0) in independent 20\% validation sets. For validation, CSF-based methylome signatures reliably distinguished between tumor types within external tissue samples and tumors from non-neoplastic controls in CSF and tissue. CSF methylome signals were observed to align closely with tissue signatures for each entity. An additional set of optimized CSF-based models, built using tumor-specific features present in tissue data, showed enhanced classification accuracy. CONCLUSIONS: CSF methylomes are reliable for liquid biopsy-based classification of the major three malignant brain tumor types. We discuss how liquid biopsies may impact brain cancer management in the future by avoiding surgical risks, classifying unbiopsiable tumors, and guiding surgical planning when resection is indicated.

MagMeDIP kit
IPure kit

Share this article

December, 2022


Products used in this publication

  • MagMeDIP qPCR Kit box
    MagMeDIP Kit
  • default alt
    IPure kit v2


  • Symposium: "Signaling through Chromatin"
    Grenoble, France
    Oct 2-Oct 4, 2023
  • EMBL Symposium: The non-coding genome
    Heidelberg, Germany
    Oct 11-Oct 14, 2023
    Crete, Greece
    Oct 15-Oct 20, 2023
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics